Coming Soon
HIV CURE-related Studies
A5369
| Goal | To evaluate the safety and tolerability of two different HIV vaccines. To see if the vaccines improve the immune system’s ability to fight HIV. |
| Who is eligible to participate | HIV-infected men and women on ART with HIV-1 RNA <50 for ≥ 2 years, current CD4 >500, and nadir CD4 >350. |
| Medication | p24CE1/2 pDNA vaccine and/or full-length p55gag pDNA vaccine |
| Duration | 48 weeks |
| Compensation | Visits – $50, Optional Leukapheresis Procedure(s) – $150, Total – $600- $900. Travel & parking compensation are offered as well. |
VOR-07
| Goal | To evaluate the safety and tolerability of combination therapy with VRC07-523LS and VOR in HIV-infected participants on cART. |
| Who is eligible to participate | Healthy men and women of any race with HIV-1 infection, ages 18 through 64, suppressed on ART therapy for > 24 months. Eligible participants must have a CD4 cell count ≥ 300 cells/mm3. |
| Medication | Vorinostat and VRC07-523LS |
| Duration | 36 weeks |
| Compensation | Total – $2850. Travel & parking compensation are offered as well. |
A5357
| Goal | Long-Acting Cabotegravir + VRC01LS is safe and will keep patient’s HIV virus suppressed. |
| Who is eligible to participate | HIV infected men and women ≥ 18 years of age. CD4 ≥ 350, HIV RNA < 50 for 2 years. |
| Medication | Oral and injectable Cabotegraivir and VRC01LS Infusions |
| Duration | Step 1- 9 weeks: Step 2- 48 weeks: Step 3- 48 weeks |
| Compensation | Step 1: $300; Step 2: $1,600; Step 3 $300. Travel & parking compensation are offered as well. |
The M & M Study
| Goal | Safety and ability of 2 different HIV vaccines to provoke an immune response within the body. |
| Who is eligible to participate | HIV infected men and women 18-60 years of age. CD4 ≥ 350, HIV RNA < 50 for 2 years. |
| Medication | 2 HIV vaccines: MVA.tHIVconsv3 (M3) and MVA.tHIVconsv4 (M4) |
| Duration | 4 months |
| Compensation |
HIV Treatment & Overall Health Studies
A5359
| Goal | HIV treatment using Long-Acting injectable ART will be a more successful therapy compared to a Standard of Care oral ART regimen in keeping previously non-adherent, HIV-infected individuals on treatment and virologically suppressed. |
| Who is eligible to participate | HIV infected men and women ≥ 18 years of age. HIV
RNA > 200 copies/mL, non-adherent to HIV medication. |
| Medication | Oral and Long-Acting injectable Cabotegravir and Rilpivirine |
| Duration | Up to 3.5 years |
| Compensation |
GS-US-380-4580
| Goal | Effectiveness of switching from an ART regimen of 2 NRTIs and a third agent to Bictegravir, a fixed dose combination. |
| Who is eligible to participate | HIV infected men and women ≥ 18 years of age who self-describe as Black, African American, or mixed race, including Black. HIV RNA < 50 copies/mL, on a stable regimen of two NRTIs and a third agent for ≥ 6 months prior to screening. |
| Medication | Bictegravir |
| Duration | At least 48 weeks |
| Compensation |